Biosyent Inc
XTSX:RX
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
8.24
11.45
|
Price Target |
|
We'll email you a reminder when the closing price reaches CAD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one RX stock under the Base Case scenario is 9.51 CAD. Compared to the current market price of 11.25 CAD, Biosyent Inc is Overvalued by 15%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Biosyent Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for RX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Biosyent Inc
Balance Sheet Decomposition
Biosyent Inc
Current Assets | 30.1m |
Cash & Short-Term Investments | 17.4m |
Receivables | 5.8m |
Other Current Assets | 6.9m |
Non-Current Assets | 11.4m |
Long-Term Investments | 8.4m |
PP&E | 1.3m |
Intangibles | 1.2m |
Other Non-Current Assets | 495.5k |
Current Liabilities | 4.9m |
Accounts Payable | 4.5m |
Other Current Liabilities | 435.9k |
Non-Current Liabilities | 1.2m |
Long-Term Debt | 942.2k |
Other Non-Current Liabilities | 210k |
Earnings Waterfall
Biosyent Inc
Revenue
|
33.8m
CAD
|
Cost of Revenue
|
-6.8m
CAD
|
Gross Profit
|
27m
CAD
|
Operating Expenses
|
-18.7m
CAD
|
Operating Income
|
8.3m
CAD
|
Other Expenses
|
-1.2m
CAD
|
Net Income
|
7.2m
CAD
|
Free Cash Flow Analysis
Biosyent Inc
CAD | |
Free Cash Flow | CAD |
In Q2 2024, BioSyent reported record revenues of just under $9 million, up 12% year-over-year, driven by strong performances across its Canadian pharmaceutical brands. EBITDA for the quarter exceeded $2 million, with net income just under $1.6 million. The company has achieved its 56th consecutive profitable quarter, aided by innovative product launches and strategic investments. BioSyent’s EBITDA and net income margins grew to 25% and 20%, respectively. The company expects continued revenue and profit growth, with new products and strategic acquisitions on the horizon, including a promising endocrinology product slated for a 2026 launch.
What is Earnings Call?
RX Profitability Score
Profitability Due Diligence
Biosyent Inc's profitability score is 71/100. The higher the profitability score, the more profitable the company is.
Score
Biosyent Inc's profitability score is 71/100. The higher the profitability score, the more profitable the company is.
RX Solvency Score
Solvency Due Diligence
Biosyent Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Biosyent Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RX Price Targets Summary
Biosyent Inc
According to Wall Street analysts, the average 1-year price target for RX is 11.22 CAD with a low forecast of 11.11 CAD and a high forecast of 11.55 CAD.
Dividends
Current shareholder yield for RX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. BioSyent, through its wholly owned subsidiaries BioSyent Pharma Inc. (BioSyent Pharma) and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary of BioSyent, operates in the non-chemical insecticide business. BioSyent products include Combogesic, Aguettant System, Cathejell, Cysview, FeraMAX 150, FeraMAX Powder, Proktis-M, RepaGyn, and TIBELLA. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Aguettant System are used for a variety of injectable medications in hospitals and the acute care setting. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. RepaGyn for the healing of the vaginal mucosa and the treatment of vaginal dryness.
Contact
IPO
Employees
Officers
The intrinsic value of one RX stock under the Base Case scenario is 9.51 CAD.
Compared to the current market price of 11.25 CAD, Biosyent Inc is Overvalued by 15%.